Literature DB >> 7248527

Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry.

D Chiu, B Lubin, B Roelofsen, L L van Deenen.   

Abstract

A membrane lipid abnormality induced by sickling and found as a permanent alteration in the irreversibly sickled cell (ISC) is the rearrangement of phosphatidyl ethanolamine (PE) and phosphatidyl serine (PS) from the inner to the exterior side of the lipid bilayer. Since PS can provide a catalytic surface for the binding of blood coagulation factors and thus can exhibit procoagulant activity, we investigated the influence of oxy and deoxy reversibly sickled cells (RSC) ass well as ISC on clotting in vitro. Red blood cells (RBC), as the source of phospholipid, were added to platelet-poor citrated plasma containing Russell's viper venom (RVV) and clotting time was measured after recalcification. The clotting time after addition of normal RBC and oxy-RSC was similar to the saline blank (100 sec). In contrast, both oxy-ISC and deoxy completely sickled RSC shortened clotting time by 30%. Using liposomes prepared with identical phospholipid composition to the outer lipid leaflet of either normal RBC, RSC or ISC clotting times similar to those with intact cells were achieved. Since the liposomes did not contain protein, accentuation of clotting appears to be related to abnormal phospholipid organization, in particular to the abnormal exposure to aminophospholipids on the outer surface of the membrane. This abnormality may contribute to the pathogenesis of the vaso-occlusive episode in sickle cell anemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248527

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Sickle cell disease: old discoveries, new concepts, and future promise.

Authors:  Paul S Frenette; George F Atweh
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 2.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 4.  Sickle cell states and the anaesthetist.

Authors:  D W Esseltine; M R Baxter; J C Bevan
Journal:  Can J Anaesth       Date:  1988-07       Impact factor: 5.063

5.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

6.  Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes.

Authors:  S H Embury; M R Clark; G Monroy; N Mohandas
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats.

Authors:  S K Jain
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 9.  Sickle Cell Trait from a Metabolic, Renal, and Vascular Perspective: Linking History, Knowledge, and Health.

Authors:  Caroline K Thoreson; Michelle Y O'Connor; Madia Ricks; Stephanie T Chung; Anne E Sumner
Journal:  J Racial Ethn Health Disparities       Date:  2015-09

10.  Tissue type plasminogen activator antigen and activity in sickle cell disease.

Authors:  R B Francis
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.